AlphaCentric Advisors LLC Invests $1.14 Million in Takeda Pharmaceutical Company Limited (NYSE:TAK)

AlphaCentric Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the third quarter, according to the company in its most recent filing with the SEC. The fund purchased 80,000 shares of the company’s stock, valued at approximately $1,138,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Blair William & Co. IL boosted its position in Takeda Pharmaceutical by 6.5% in the first quarter. Blair William & Co. IL now owns 12,649 shares of the company’s stock worth $176,000 after purchasing an additional 777 shares during the last quarter. Dorsey & Whitney Trust CO LLC increased its holdings in Takeda Pharmaceutical by 4.6% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 18,197 shares of the company’s stock worth $253,000 after buying an additional 798 shares during the last quarter. SG Americas Securities LLC boosted its stake in Takeda Pharmaceutical by 5.4% in the first quarter. SG Americas Securities LLC now owns 16,099 shares of the company’s stock valued at $224,000 after acquiring an additional 824 shares during the last quarter. Catalytic Wealth RIA LLC grew its position in shares of Takeda Pharmaceutical by 4.0% during the 2nd quarter. Catalytic Wealth RIA LLC now owns 21,703 shares of the company’s stock valued at $281,000 after acquiring an additional 841 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after purchasing an additional 859 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $14.05 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The business’s 50 day simple moving average is $14.46 and its 200 day simple moving average is $13.80. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The company has a market cap of $44.71 billion, a price-to-earnings ratio of 24.22, a PEG ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.